Comparison between Tatva Chintan Pharma Chem IPO and Windlas Biotech IPO.
Tatva Chintan Pharma Chem IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Windlas Biotech IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Tatva Chintan Pharma Chem IPO is up to ₹500.00 Cr whereas the issue size of the Windlas Biotech IPO is up to ₹401.54 Cr. The final issue price of Tatva Chintan Pharma Chem IPO is ₹1,083.00 per share and of Windlas Biotech IPO is ₹460.00 per share.
| Tatva Chintan Pharma Chem IPO | Windlas Biotech IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹5 per share |
| Issue Price (Lower) | ₹1,073.00 per share | ₹448.00 per share |
| Issue Price (Upper) | ₹1,083.00 per share | ₹460.00 per share |
| Issue Price (Final) | ₹1,083.00 per share | ₹460.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 13 shares | 30 shares |
| Fresh Issue Size | 20,77,562 shares | 35,86,956 shares |
| Fresh Issue Size (Amount) | up to ₹225.00 Cr | up to ₹165.00 Cr |
| OFS Issue Size | 25,39,242 shares | 51,42,067 shares |
| OFS Issue Size (Amount) | up to ₹275.00 Cr | up to ₹236.54 Cr |
| Issue Size Total | 46,16,804 shares | 87,29,023 shares |
| Issue Size Total (Amount) | up to ₹500.00 Cr | up to ₹401.54 Cr |
Tatva Chintan Pharma Chem IPO opens on Jul 16, 2021, while Windlas Biotech IPO opens on Aug 04, 2021. The closing date of Tatva Chintan Pharma Chem IPO and Windlas Biotech IPO is Jul 20, 2021, and Aug 06, 2021, respectively.
| Tatva Chintan Pharma Chem IPO | Windlas Biotech IPO | |
|---|---|---|
| Anchor Bid Date | Jul 15, 2021 | Aug 03, 2021 |
| Issue Open | Jul 16, 2021 | Aug 04, 2021 |
| Issue Close | Jul 20, 2021 | Aug 06, 2021 |
| Basis Of Allotment (Tentative) | Jul 26, 2021 | Aug 11, 2021 |
| Initiation of Refunds (Tentative) | Jul 27, 2021 | Aug 12, 2021 |
| Credit of Share (Tentative) | Jul 28, 2021 | Aug 13, 2021 |
| Listing date (Tentative) | Jul 29, 2021 | Aug 16, 2021 |
| Anchor Lockin End date 1 | Aug 25, 2021 | Sep 10, 2021 |
| Anchor Lockin End date 2 | Oct 24, 2021 | Nov 09, 2021 |
Tatva Chintan Pharma Chem IPO P/E ratio is , as compared to Windlas Biotech IPO P/E ratio of .
| Tatva Chintan Pharma Chem IPO | Windlas Biotech IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 100 | 78 | ||||
| Promoter Shareholding (Post-Issue) | 79.17 | 65.16 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹2400.48 Cr. | ₹1002.54 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Tatva Chintan Pharma Chem IPO Retail Individual Investors (RII) are offered 16,15,882 shares while in Windlas Biotech IPO retail investors are offered 16,15,882 shares. Qualified Institutional Buyers (QIB) are offered 9,23,361 shares in Tatva Chintan Pharma Chem IPO and 17,45,804 shares in Windlas Biotech IPO.
| Tatva Chintan Pharma Chem IPO | Windlas Biotech IPO | |
|---|---|---|
| Anchor Investor Reservation | 13,85,040 shares | 26,18,706 shares |
| Market Maker Reservation | ||
| QIB | 9,23,361 shares | 17,45,804 shares |
| NII | 6,92,521 shares | 13,09,354 shares |
| RII | 16,15,882 shares | 30,55,159 shares |
| Employee | ||
| Others | ||
| Total | 46,16,804 shares | 87,29,023 shares |
Tatva Chintan Pharma Chem IPO subscribed 180.36x in total, whereas Windlas Biotech IPO subscribed 22.44x.
| Tatva Chintan Pharma Chem IPO | Windlas Biotech IPO | |
|---|---|---|
| QIB (times) | 185.23x | 24.40x |
| NII (times) | 512.22x | 15.73x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 35.35x | 24.22x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 180.36x | 22.44x |
